Broad and potent neutralizing mAbs are elicited in vaccinated individuals following Delta/BA.1 breakthrough infection
Seow, J.; Shalim, Z. A.; Graham, C.; Kimuda, S.; Pillai, A.; Lechmere, T.; Kurshan, A.; Khimji, A.; Snell, L.; Nebbia, G.; Mant, C.; Waters, A.; Fox, J.; Malim, M. H.; Doores, K. J.
Show abstract
Despite the success of COVID-19 vaccines in preventing infection and/or severe disease, with the emergence of SARS-CoV-2 variants of concern (VOC) which encode mutations in Spike, and the waning of vaccine induced immunity, there has been an increase in SARS-CoV-2 infections in vaccinated individuals which leads to increased serum neutralization breadth. However, how exposure to a heterologous Spike broadens the neutralizing response at the monoclonal antibody (mAb) level is not fully understood. Through isolation of 119 mAbs from three individuals receiving two-doses of BNT162b2 vaccine before becoming delta or omicron/BA.1-infected, we show that breadth arises from re-activation and maturation of B cells generated through previous COVID-19 vaccination rather than a de novo response specific to the VOC Spike. Isolated mAbs frequently show reduced neutralization of current circulating variants including BA.2.75.2, XBB, XBB.1.5 and BQ.1.1 confirming continuous selective pressure on Spike to evolve and evade neutralization. However, isolation of mAbs that display effective cross-neutralization against all variants indicate the presence of conserved epitopes on RBD and a lesser extent NTD. These findings have implications for selection of Spike antigens for next-generation COVID-19 vaccines.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Broadly neutralizing antibodies targeting a conserved silent face of spike RBD resist extreme SARS-CoV-2 antigenic drift 97%
- Protective effect and molecular mechanisms of human non-neutralizing cross-reactive spike antibodies elicited by SARS-CoV-2 mRNA vaccination 97%
- Crimean-Congo Hemorrhagic Fever Survivors Elicit Protective Non-Neutralizing Antibodies that Target 11 Overlapping Regions on Viral Glycoprotein GP38 97%
Similar papers in this journal
- Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection 97%
- Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies 96%
- Sequence signatures of two IGHV3-53/3-66 public clonotypes to SARS-CoV-2 receptor binding domain 96%
Similar papers in this journal
Similar papers in this journal
- Broad SARS-CoV-2 Neutralization by Monoclonal and Bispecific Antibodies Derived from a Gamma-infected Individual 98%
- Bispecific antibodies combine breadth, potency, and avidity of parental antibodies to neutralize sarbecoviruses 96%
- Ancestral SARS-CoV-2 immune imprinting persists on RBD but not NTD after sequential Omicron infections 96%
Similar papers in this journal
- A SARS-CoV-2 variant of concern triggers Fc effector function with increased cross-reactivity 96%
- Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4 and BA.5 in patients receiving monoclonal antibodies 96%
- A potently neutralizing and protective human antibody targeting antigenic site V on RSV and hMPV fusion glycoprotein 96%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.